Trial Profile
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 691751 in Healthy Male Subjects
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 03 Mar 2016
Price :
$35
*
At a glance
- Drugs BI 691751 (Primary)
- Indications Atherosclerosis
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 03 Sep 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 03 Jun 2014 New trial record